Cost-effectiveness analysis of irinotecan plus fluorouracil/folinic acid compared with fluorouracil/folinic acid alone as first-line treatment for advanced colorectal cancer

Clinical and Translational Oncology

Volumn 5, Issue 9, 2003, Pages 517-523

  Hart, Warren Mark ^a   Rubio Terrés, Carlos ^b   Pronk, Linda ^c   Kobina, Svetlana ^d   Rubio, Eduardo Díaz ^e  

^a EcoStat Consulting Group   (Spain)

^b HERO Consulting   (Spain)

^c Aventis Pharma   (Spain)

^d SANOFI   (France)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Colorectal neoplasm; Cost analysis; Economic evaluation; Irinotecan

Indexed keywords

EID: 45249110904     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wingo PA, Tons T, Bolden S, et al. Cancer statistic, 1995. CA Cancer J Clin 1995;45:8-30.
2. Cáncer en España. Madrid: Ministerio de Sanidad y Consumo, 1993.
3. Regidor E, Rodríguez C, Gutiérrez F, et al. Indicadores de salud. Tercera evaluación en España del programa regional europeo. Salud para todos. Madrid: Ministerio de Sanidad y Consumo, 1995.
4. Cancer incidence in five continents. Vol IV, V, VI, y VII (1982, 1987, 1992, 1995 y 1997). IARC Scientifics publications, N 42, 88,107,120,132.
5. Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. En: Liu LF, editor. Advances in Pharmacology. New York: Academic Press, 1994;29B: p.73-92.
6. Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353: 391-9.
7. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
8. Rougier P, Van Custem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
9. Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil campared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
10. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
11. Consejo general de colegios oficiales de farmacéuticos de España. Catalogue of Pharmaceutical Specialties, Madrid: 2001.
12. Gisbert R, Brosa M. Base de datos de costes sanitarios. Versión 1.1c. Barcelona: Soikos, 2001.
13. Cunningham D, Falk S, Jackson DL. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002; 86:1677-83.
14. Montero MC, Valdivia ML, Carvajal E, et al. Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm Worls Sci 1994;16(4):187-92.
15. Schmitt C, Levy-Piedbois C, Frappé M, et al. Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer. Annals of Oncology 2000;11(Suppl. 4):47.
16. Plans-Rubió P. Cost-effectiveness of pharmacologic treatments for the reduction of blood lipids. Med Clin (Barc) 1995;105:327-33.
17. Plans-Rubió P. Cost-effectiveness of cardiovascular prevention programs in Spain. Int J Technol Assess Health Care 1998;14:320-30.